Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib Maintenance Post Cellular Therapies in Ph+ ALL
NCT07040982Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Dec 2025
- Primary completion
- Jun 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of asciminib in acute lymphoblastic leukemia (ALL), sponsored by City of Hope. Primary endpoint: Incidence of adverse events at 28 days. Started Dec 2025; status: recruiting.
02
Drugs
asciminib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07040982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040982.